Search Results
TGR-1202, ublituximab and ibrutinib combination for advanced CLL and NHL
Tolerability and Activity of Chemo-Free Triplet Combination of TGR-1202 (Ublituximab)...
Combining ublituximab with the novel PI3K inhibitor TGR-1202 for CLL
Ibrutinib combined with TGR-1202 in CLL and mantle cell lymphoma (MCL): preliminary results
Updates from a Phase I clinical trial examining ublituximab in combination with TGR-1202
Ibrutinib and ublituximab – a promising combination regimen for treating CLL?
Dr. Chavez on Combination of Ibrutinib Plus Ublituximab in CLL
TGR-1202 in CLL and non-Hodgkin lymphoma
Results for the Combination of Ublituximab and Ibrutinib in CLL
What makes TGR-1202 different from other PI3K inhibitors?
TGR-1202, a next generation PI3K-delta inhibitor in CLL and B-cell lymphomas
Safety profiles of idelalisib, duvelisib and TGR-1202 in treating CLL
